Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC). - Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).

Kansai Medical University Hirakata Hospital0 个研究点目标入组 25 人开始时间: 2010年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Uncontrolled infection or Serious medical complications 2)massive pleural effusion or ascites. (accept controrable pleural effusion with OK-432) 3)current or previous treated brain metastasis 4)severe cardiac disease 5)uncontrolled diabetes mellitus 6)receiving anticoagulant drug(except Aspirin under 325mg/day) 7)current or previous history of hemoptysis(>=2.5ML) due to NSCLC 8)history of hemoptysis(over 1 week) or receive oral/i.v. hemostatic drug 9)uncontrolled hyper tension 10)current or previous (within the last 1 year) history of GI perforation 11)interstitial pneumonia or lung fibrosis evident on CT 12)history of drug induced interstitial pneumonia 13)Patient who has been scheduling operation for examination period 14)treatment history of carboplatin, pemetrexed and bevacizumab 15)severe drug allergy 16)Patient who cannot or doesn't hope administer multivitamin and vitamin B12 17)active concomitant malignancy 18)severe psychological disease 19)pregnant or lactating women or those who declined contraception 20)those judged to be not suitable by the attending physician

发起方

Kansai Medical University Hirakata Hospital